Abeona Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Abeona Therapeutics's estimated annual revenue is currently $5.3M per year.
- Abeona Therapeutics received $92.0M in venture funding in October 2017.
- Abeona Therapeutics's estimated revenue per employee is $28,254
- Abeona Therapeutics's total funding is $249.7M.
Employee Data
- Abeona Therapeutics has 189 Employees.
- Abeona Therapeutics grew their employee count by 36% last year.
Abeona Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President & CEO | Reveal Email/Phone |
2 | CFO and Principal Financial Officer | Reveal Email/Phone |
3 | VP, Regulatory Affairs at Abeona Therapeutics | Reveal Email/Phone |
4 | VP Market Access | Reveal Email/Phone |
5 | VP, Program Leadership & Clinical Operations | Reveal Email/Phone |
6 | VP - Head Regulatory Affairs | Reveal Email/Phone |
7 | VP Business Development | Reveal Email/Phone |
8 | VP, Investor Relations and Corporate Communications | Reveal Email/Phone |
9 | VP, HR | Reveal Email/Phone |
10 | Head Facilities Engineer | Reveal Email/Phone |
Abeona Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | 0% | N/A | N/A |
#2 | $3.7M | 24 | 41% | $44M | N/A |
#3 | $6.2M | 40 | -7% | N/A | N/A |
#4 | $42M | 271 | -1% | N/A | N/A |
#5 | $12.7M | 82 | 0% | $10M | N/A |
#6 | $2.5M | 16 | 0% | N/A | N/A |
#7 | $7.5M | 45 | 0% | $51.6M | N/A |
#8 | $0.2M | 1 | -50% | N/A | N/A |
#9 | $4.3M | 26 | -16% | $3.3M | N/A |
#10 | $3.7M | 24 | 4% | N/A | N/A |
What Is Abeona Therapeutics?
Abeona Therapeutics Inc.(NASDAQ: $ABEO)is a leading clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV-NAGLU), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type B (MPS IIIB). Abeona is also developing ABO-201 (AAV-CLN3) gene therapy for CLN3 disease, ABO-202 (AAV-CLN1) for treatment of CLN1 disease, EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona is developing a proprietary vector platform, AIM, for next generation product candidates. For more information, visit www.abeonatherapeutics.com.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$249.7M
Total Funding
189
Number of Employees
$5.3M
Revenue (est)
36%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Abeona Therapeutics News
Abeona Therapeutics (NASDAQ:ABEO) Coverage Initiated by Analysts at StockNews.com. Posted by admin on Apr 14th, 2022.
Abeona Therapeutics (NASDAQ: ABEO) recently received a number of ratings updates from brokerages and research firms:.
NEW YORK and CLEVELAND, March 31, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and...
Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it has retained Jefferies ...
NEW YORK and CLEVELAND, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in ...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $42.6M | 189 | 8% | N/A |
#2 | $21.2M | 189 | 7% | N/A |
#3 | $30.1M | 189 | N/A | N/A |
#4 | $52.6M | 189 | 2% | N/A |
#5 | $56.1M | 189 | 6% | N/A |
Abeona Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2013-12-17 | $0.8M | Undisclosed | Multiple | Article |
| 2014-12-02 | $3.6M | Undisclosed | Multiple | Article |
| 2015-07-30 | $8.5M | Undisclosed | Article | |
| 2017-10-18 | $92.0M | Undisclosed | Jefferies LLC | Article |